Last week, the Oregon Health Authority (OHA) awarded a pair of psilocybin manufacturer licenses. First two! Congrats to Tori Arbrust of Satori Farms PDX, and Andres Met of Satya Therapeutics, known to many of us from the Oregon cannabis program. We should also congratulate OHA, which had aimed to issue manufacturing licenses by the end
Among the emerging medical uses for MDMA and psilocybin is their relative dimethyltryptamine (DMT). Although a Schedule I drug in the United States, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Much of this research is occurring outside of
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so
Our marketing people somehow determined that I should write a piece comparing Oregon’s new psilocybin program with The Last of Us– which is a zombie show about a global pandemic caused by a mass fungal infection. Apparently this type of content gets a lot of eyeballs. I said: I don’t want to watch a whole
It seems that the Oregon psilocybin program is off to a slow start. The Oregon Health Authority (OHA) did a good job meeting the Measure 109 rulemaking and development deadlines, including by opening the license application portal back on January 2. Still, a slew of factors, some of them structural, have tempered program launch. The
The 2023 Oregon legislative session commenced last week. It’s a regular session this year, so we’re in for a longer stretch– a 160 day calendar, versus the 35 day affair we see in even-numbered years. For better or worse, the legislature has ample time to tinker with our brand-new psilocybin program here in Oregon. Going
Register Here Harris Sliwoski attorneys, Paul Coble, Griffen Thorne, and Vincent Sliwoski, will be presenting on the “Legal and Regulatory Landscape for Psychedelics” in the following CLE webinar on January 12th, 2023, hosted by The Seminar Group. “This program will provide an overview of emerging drug therapies, including psilocybin, ketamine infusion clinics, MDMA and other
We’re finally ready to launch. After a two-year advisory and developmental period, the Oregon Health Authority (OHA) has adopted and released final rules to implement a first-of-its-kind, regulated psychedelics program. You can find the new rules here. OHA will also begin accepting applications for psilocybin service centers, testing labs, manufacturers and facilitators next Monday, January
Since Denver became the first U.S. jurisdiction to decriminalize psilocybin in 2019, a number of cities across the country – including, most notably, Oakland and Santa Cruz in California – have decriminalized psychedelics in various forms. And as readers of the Psychedelics Law Blog are surely aware, Oregon and now Colorado passed full-scale regulatory regimes.
